Boan Biotech Announces Successful Completion of Phase Ia Clinical Trial of BA1302 (CD228-Directed ADC) in China

Objective Responses observed in multiple types of advanced solid tumors, showing potential to treat a variety of cancersBoan Biotech today announced the completion of the monotherapy dose-escalation p...

VOLUNTARY ANNOUNCEMENT COMPLETION OF PHASE IA CLINICAL TRIAL OF BA1302 (CD228-DIRECTED ADC) IN CHINA

INSIDE INFORMATION ANNOUNCEMENT PROFIT WARNING

NOTICE OF BOARD MEETING

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026

Boan Biotech Submits BLA for Aflibercept Intravitreous Injection in Brazil

Boan Biotech announced today that it has submitted a Biologics License Application (BLA) to the Brazilian Health Regulatory Agency (ANVISA) for the company’s Aflibercept Intravitreous Injection ...

VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR AFLIBERCEPT INTRAVITREOUS INJECTION IN BRAZIL

China’s CDE Accepts IND Application for Boan Biotech’s BA1203 (A Masked Anti-PD-1/IL-2 Fusion Protein)

Boan Biotech announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for ...

VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026